[
    [
        {
            "time": "2018-03-12",
            "original_text": "恒瑞医药(600276.SH)：“缬沙坦氨氯地平片(I)”获得药品注册证书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "药品注册证书",
                    "缬沙坦氨氯地平片"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)：“缬沙坦氨氯地平片(I)”获得药品注册证书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-12",
            "original_text": "乐普医疗:君实生物PD-1单抗新药申请获受理,乐普肿瘤及心血管外延布局持续推进",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "君实生物",
                    "PD-1单抗",
                    "新药申请"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "乐普医疗:君实生物PD-1单抗新药申请获受理,乐普肿瘤及心血管外延布局持续推进",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-12",
            "original_text": "北上资金调仓换股，重新看好茅台等新宠",
            "features": {
                "keywords": [
                    "北上资金",
                    "调仓换股",
                    "茅台"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金调仓换股，重新看好茅台等新宠",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-12",
            "original_text": "医改联动药企创新加速，优质龙头迎机遇",
            "features": {
                "keywords": [
                    "医改",
                    "药企创新",
                    "优质龙头"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医改联动药企创新加速，优质龙头迎机遇",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-12",
            "original_text": "研发投入约1535万元，恒瑞4类化药获批",
            "features": {
                "keywords": [
                    "研发投入",
                    "恒瑞",
                    "化药获批"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "研发投入约1535万元，恒瑞4类化药获批",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]